All GLG News Analyses Filed Under: Ophthalmology

1. Wet AMD. 2. Macular edema. 3. Intravitreal injection.

1. Lucentis. 2. Avastin. 3. Cost.

This was a retrospective clinical study of 21 eyes from 12 patients who identified themselves as being dissatisfied with their visual acuity and were interested either in initial or enhancement refractive surgery in order to improve their acuity. Uncorrected visual acuity was documented in each eye....

Sicrolimus is a novel agent that has a broad range of activities that is entering the Ophthalmic Arena.  Phase I Data has shown its safety profile in treating two large markets: Age Related Macular Degeneration and Diabetic Macular Edema.  Given its success in cardiology, it is a promising...

This study shows that Bausch and Lomb's Zylet is as good and safer than Alcon's Tobradex for the management of Blepharitis.  Blepharitis is a large problem affecting many patients.  This could be a large market opportunity.

Biovitrum reports Phase II results of its new glaucoma medication. Although the mechanism of action of this glaucoma drug is novel and targets the site of disease in glaucoma, its clinical results are very disappointing.  A 10% reduction in intraocular pressure is not enough to make a clinical...

The CATT Trial will prospectively compare lucentis and avastin head to head in the management of Age Related Macular Degeneration.  Lucentis costs 40X more than Avastin for ocular dosing; and many suspect that they both are similiar in efficacy.  If CATT confirms this, it sink Lucentis Sales...

Contacts can successfully be worn with pediatric patinets as early as 10 years of age.  With that being said, patient selection is crucial.  You may encounter 10 year old patients that are as responsible as 7 year olds and vice versa.

Biovitrum may have discovered a new adjunct to our existing prostaglandin analogs.  Currently, the prostaglandins generally lower patients pressures by 30-40% therefore making them first line therapy.  If this new 5-HT2A drug can lower pressure an additional 10%, this drug would find a home...

1. Glaucoma therapy 2. IOP reduction 3. Combined therapy